Phuturdex › Diseases › Hemoglobinopathies
Drugs in development · updated 30 October 2026
Hemoglobinopathies: drugs in development
As of 30 October 2026 there are 16 active clinical trials (recruiting or ongoing, phases I–III) on 22 drugs for hemoglobinopathies. 7 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| Etavopivat | III | 1 | NCT04624659 |
| EDIT-301 | I–II | 2 | NCT05444894 |
| CD34 | I–II | 1 | NCT01966367 |
| Senicapoc | II | 1 | NCT07282210 |
| SNH-119014 | I | 1 | NCT07087262 |
| RM-004 | Early I | 1 | NCT06107400 |
| YOLT-204 | Early I | 1 | NCT07190001 |
Sorted by most advanced phase and number of active trials.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| CTX001 | III | 4 | NCT04208529 |
| Mycophenolate MofetilMycophenolate, Cellcept | II | 3 | NCT06872333 |
| BusulfanBusulphan, Busulfex® | II | 2 | NCT06872333 |
| CyclophosphamideCyclophosphamid, Cytoxan | II | 2 | NCT06872333 |
| FludarabineFludara, FLUDARABIN | II | 2 | NCT06872333 |
| TacrolimusEnvarsus XR, Prograf® | II | 2 | NCT06872333 |
| ThymoglobulinRabbit Anti thymocyte globulin, Rabbit ATG | II | 2 | NCT06872333 |
| AlemtuzumabCampath, Lemtrada® | II | 1 | NCT06872333 |
| ClofarabineClolar®, Evoltra® | II | 1 | NCT04644016 |
| CyclosporineCyclosporine A, Cyclosporin Capsules | II | 1 | NCT04644016 |
| HydroxyureaHydroxycarbamide, Hydroxycarbamid | II | 1 | NCT06490601 |
| PlerixaforMozobil, Plerixafor Accord® | II | 1 | NCT06872333 |
| SirolimusRapamycin, Scomara® | II | 1 | NCT06872333 |
| ThalidomideThalomid®, Thalidomide Lipomed® | II | 1 | NCT06490601 |
| PentostatinNipent® | I | 1 | NCT03249831 |
Sorted by most advanced phase and number of active trials.
All 22 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Sickle-cell disease 73 drugs
- Beta thalassemia 34 drugs
- Thalassemia 21 drugs
- Vaso-occlusive crisis 12 drugs
- Graft-versus-host disease 49 drugs
- Anemia 52 drugs
- Sickle cell trait 5 drugs
- Acute chest syndrome 3 drugs
- Aplastic anemia 43 drugs
- Myelodysplastic Syndromes 203 drugs
- Diamond-Blackfan anemia 8 drugs
- Cognitive dysfunction 94 drugs
Broader categories
- Congenital, Hereditary, and Neonatal Diseases and Abnormalities 4 drugs
- Congenital hemolytic anemia 4 drugs
- Hemolytic anemia 6 drugs
- Anemia 52 drugs
- Hematologic Diseases 57 drugs
- Genetic disease 33 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: NLM MeSH; NLM MeSH term: D006453 “Hemoglobinopathies”.